Research programme: metabotropic glutamate receptor modulator - Prescient

Drug Profile

Research programme: metabotropic glutamate receptor modulator - Prescient

Alternative Names: PRE 703

Latest Information Update: 17 Jan 2011

Price : $50

At a glance

  • Originator Prescient NeuroPharma
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anxiety disorders

Most Recent Events

  • 17 Jan 2011 No development reported - Preclinical for Anxiety disorders in Canada (unspecified route)
  • 05 Oct 2005 PRE 703 is available for licensing
  • 16 Sep 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top